Brukinsa 80mg Capsule
Inclusive of all taxes
Free Express Secure Delivery
Protective climate-sealed dispatch across India within 4 to 24 hours.
Order through WhatsAppFinancial Assistance Available
Contact our oncology support team to check your eligibility for manufacturer patient assistance programs (PAP) for Brukinsa 80mg Capsule.
About this medicine
Brukinsa 80mg Capsule (ZANUBRUTINIB)is a prescription oncology medicine. Below is educational product information — follow your doctor's advice for dose and use.
Brukinsa 80mg Capsule is a prescription antineoplastic medication containing zanubrutinib, a targeted small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It is indicated for the treatment of specific hematologic malignancies, particularly in adult patients who have received at least one prior systemic therapy. By selectively binding to and inhibiting the BTK protein, zanubrutinib disrupts the B-cell receptor signaling pathway, preventing the proliferation and survival of malignant B cells. Administered orally in capsule form, treatment with This medicine must be initiated and managed under the supervision of a qualified oncologist. This medication requires careful clinical evaluation prior to and during therapy; baseline blood work, including complete blood counts and liver function assessments, must be routinely monitored. Special caution is required for patients with pre-existing hepatic impairment, cardiac arrhythmias, or severe hypertension. Brukinsa is strictly contraindicated during pregnancy and breastfeeding due to the risk of fetal harm and adverse effects on nursing infants. Women of childbearing potential and male patients with female partners of reproductive potential must utilize effective contraception during treatment and for the recommended duration following the final dose.
Quick Facts
What if you miss a dose?
If you miss a dose of Brukinsa 80mg Capsule, take it as soon as you remember on the same day. Return to your normal dosing schedule the following day.
Uses of Brukinsa 80mg Capsule
Side Effects of Brukinsa 80mg Capsule
Oncology medicines should be administered strictly under medical supervision. Inform your oncologist immediately if you experience adverse symptoms.
Clinical Safety Advice for Brukinsa 80mg Capsule
Follow expert clinical guidelines regarding interactions, precautions, and medical conditions when taking Brukinsa 80mg Capsule.
Pregnancy UNSAFE Brukinsa 80mg Capsule is strictly unsafe during pregnancy as it can cause fetal harm and embryo-fetal toxicity. Inform your oncologist immediately if you are pregnant, suspect you may be pregnant, or plan to become pregnant. Females of reproductive potential must use highly effective contraception during treatment and continue for at least 1 week after the final dose. Male patients with female partners of reproductive potential must also use effective contraception during therapy and for at least 1 week post-treatment.
Breastfeeding is not recommended during treatment with Brukinsa 80mg Capsule. It is unknown whether zanubrutinib passes into human breast milk, but due to the potential for serious adverse reactions in nursing infants, patients should avoid breastfeeding during treatment and for at least 2 weeks following the last dose.
Brukinsa 80mg Capsule is extensively metabolized in the liver. Patients with severe hepatic impairment (Child-Pugh Class C) require a reduced dose (80mg twice daily) and close clinical monitoring. Baseline liver function tests should be conducted prior to initiating therapy and monitored regularly throughout treatment.
Alcohol consumption should be avoided or strictly minimized during treatment with Brukinsa 80mg Capsule. Concurrent alcohol use may exacerbate central nervous system side effects like dizziness and fatigue, increase the risk of liver toxicity, and worsen gastrointestinal irritation.
Brukinsa 80mg Capsule may cause fatigue, dizziness, and asthenia in some patients. Refrain from driving, operating machinery, or engaging in tasks requiring complete mental concentration until you have established how the medication affects your cognitive and physical abilities.
Storage & Delivery Protocol
Preservation and climate-safe dispatch guidelines for Brukinsa 80mg Capsule across India.
Storage Conditions
Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C. Keep capsules in their original container, protected from moisture and direct heat. Keep out of reach of children. Dispose of unused medication following hazardous drug handling standards.
Climate-Sealed Transit
Dispatched in protective, tamper-evident and moisture-sealed packaging.
Rx Verification
Prescription and genuine batch validated prior to dispatch.
Frequently Asked Questions
Have questions about your cancer prescription?
Our licensed oncology pharmacists are available to assist with medicine availability, cold-chain handling, and prescription verification.